1,025 results on '"Giant Cell Tumor of Bone surgery"'
Search Results
2. The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.
- Author
-
Costello JP 2nd, Travis LM, Jahn J, and Pretell-Mazzini JA
- Subjects
- Humans, Curettage, Female, Male, Adult, Bone Cements therapeutic use, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Transplantation methods, Bone Neoplasms surgery, Bone Neoplasms pathology, Neoplasm Recurrence, Local
- Abstract
Background: Giant cell tumor of bone (GCTB) presents a challenge in management due to its invasive nature and propensity for local recurrence. While either bone grafting (BG) or bone cement (BC) can be utilized to fill defects after intralesional curettage, the optimal treatment remains contested. The purpose of this study was to examine the impact of defect filling with BC compared with BG on recurrence rates in patients with GCTB following intralesional curettage., Methods: A random-effects model binary outcome meta-analysis was performed utilizing recurrence rate for the BC and BG groups to evaluate the risk ratio (p < 0.05 considered significant). There were 1,454 patients included., Results: Intralesional curettage with BG had a recurrence risk ratio of 1.68 (95% confidence interval [CI], 1.22-2.31, p = 0.001) when compared with BC. The overall rate of recurrence for GCTB after intralesional curettage with BC was 20.05% vs. 29.74% with BG (95% CI, 0.17-0.23 vs. 0.26-0.33, p < 0.001)., Conclusion: Intralesional curettage with BC for the treatment of GCTB demonstrated lower recurrence rates than intralesional curettage with BG. However, the rates of recurrence remain substantial for both groups, necessitating careful consideration of the benefits and potential pitfalls associated with BC vs. BG when considering salvage options after recurrences., Level of Evidence: Level III. See Instructions for Authors for a complete description of levels of evidence., Competing Interests: Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSREV/B140)., (Copyright © 2024 by The Journal of Bone and Joint Surgery, Incorporated.)
- Published
- 2024
- Full Text
- View/download PDF
3. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center.
- Author
-
Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, and Li W
- Subjects
- Humans, Retrospective Studies, Female, Male, Adult, Middle Aged, Young Adult, Treatment Outcome, Combined Modality Therapy, Neoplasm Recurrence, Local, Adolescent, Bone Density Conservation Agents therapeutic use, Follow-Up Studies, Curettage methods, Preoperative Care methods, Denosumab therapeutic use, Microwaves therapeutic use, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone drug therapy, Bone Neoplasms surgery, Bone Neoplasms drug therapy
- Abstract
Background: Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm with a high propensity for recurrence following intralesional curettage. The introduction of denosumab, a RANKL inhibitor, has shown potential in facilitating joint-sparing surgery. However, concerns exist regarding its impact on local recurrence rates. This study aimed to evaluate the efficacy and safety of combined preoperative denosumab with adjuvant microwave ablation (MWA) for the treatment of high-risk GCTB., Methods: We conducted a retrospective review of 19 patients with high-risk GCTB who underwent preoperative denosumab treatment followed by curettage and adjuvant MWA. The primary outcome measure was the local recurrence rate, with secondary outcomes including functional status assessed by the Musculoskeletal Tumor Society (MSTS) score and safety profile of the treatment., Results: In this retrospective analysis, we evaluated the outcomes of 19 patients with high-risk GCTB treated with preoperative denosumab and adjuvant MWA. The median follow-up duration was 33.1 months, 3 patients (15.8%) experienced local recurrence at a median of 21.6 months postoperatively and the local recurrence-free survival was 81.2% at two years. Notably, no patient developed lung metastasis, and all recurrences were successfully managed with repeat curettage and MWA, with a mean MSTS score of 27.3. No patient required joint replacement due to tumor recurrence, resulting in a 100% joint preservation rate., Conclusion: The combination of preoperative denosumab and adjuvant MWA is a feasible and effective strategy for the management of high-risk GCTB, providing effective local control with preserved joint function. This approach may offer a surgical alternative for young patients where joint preservation is paramount., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Validity of the Musculoskeletal Tumor Society Score for lower extremity in patients with bone sarcoma or giant cell tumour of bone undergoing bone resection and reconstruction surgery in hip and knee.
- Author
-
Sherling N, Yilmaz M, Holm CE, Petersen MM, and Fernandes L
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Osteosarcoma surgery, Osteosarcoma psychology, Osteosarcoma pathology, Young Adult, Aged, Lower Extremity surgery, Surveys and Questionnaires, Adolescent, Reproducibility of Results, Quality of Life, Sarcoma surgery, Bone Neoplasms surgery, Bone Neoplasms psychology, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Plastic Surgery Procedures methods
- Abstract
Background: The Musculoskeletal Tumor Society Score (MSTS) is widely used to evaluate functioning following surgery for bone and soft-tissue sarcoma. However, concerns have been raised about its content validity due to the lack of patient involvement during item development. Additionally, literature reports inconsistent results regarding data quality and structural validity. This study aimed to evaluate content, structural and construct validity of the Danish version of the MSTS for lower extremity (MSTS-LE)., Methods: The study included patients from three complete cohorts (n = 87) with bone sarcoma or giant cell tumour of bone who underwent bone resection and reconstruction surgery in hip and knee. Content validity was evaluated by linking MSTS items to frameworks of functioning, core outcome sets and semi-structured interviews. Data quality, internal consistency and factor analysis were used to assess the underlying structure of the MSTS. Construct validity was based on predefined hypotheses of correlation between the MSTS and concurrent measurements., Results: Content validity analysis revealed concerns regarding the MSTS. The MSTS did not sufficiently cover patient-important functions, the item Emotional acceptance could not be linked to the framework of functioning, the items Pain and Emotional acceptance pertained to domains beyond functioning and items' response options did not match items. A two-factor solution emerged, with the items Pain and Emotional acceptance loading highly on a second factor distinct from functioning. Internal consistency and construct validity showed values below accepted levels., Conclusion: The Danish MSTS-LE demonstrated inadequate content validity, internal consistency, and construct validity. In addition, our analyses did not support unidimensionality of the MSTS. Consequently, the MSTS-LE is not a simple reflection of the construct of functioning and the interpretation of a sum score is problematic. Clinicians and researcher should exercise caution when relying solely on MSTS scores for assessing lower extremity function. Alternative outcome measurements of functioning should be considered for the evaluation of postoperative function in this patient group., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. The effect of preoperative embolization on giant cell tumors of the bone localized in the iliosacral region of the pelvis.
- Author
-
Scheurer F, Kaiser D, Kobe A, Smolle M, Suter D, Spirig JM, and Müller D
- Subjects
- Humans, Female, Adult, Case-Control Studies, Male, Ilium pathology, Middle Aged, Follow-Up Studies, Prognosis, Young Adult, Pelvic Bones pathology, Pelvic Bones surgery, Curettage methods, Embolization, Therapeutic methods, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone therapy, Bone Neoplasms pathology, Bone Neoplasms surgery, Bone Neoplasms therapy, Sacrum surgery, Sacrum pathology, Preoperative Care
- Abstract
Introduction: Giant cell tumors of the bone (GCTB) are aggressive neoplasms, with rare occurrences in the posterior pelvis and sacral area. Surgical challenges in this region include the inability to apply a tourniquet and limited cementation post-curettage due to proximity to neurovascular structures, leading to potential complications. This case-control study explores the impact of preoperative embolization on GCTB located in the iliosacral region., Methods: Five surgeries (January-December 2021) for pelvic GCTB (3 sacrum, 2 posterior ilium) were performed on four patients. Diagnosis was confirmed through preoperative CT-guided biopsies. One surgery involved curettage with PMMA cement filling, while four surgeries had curettage without cavity filling. Preoperative embolization of the tumor feeding vessel occurred approximately 16 h before surgery in two cases. Denosumab treatment was not administered., Results: Tumor volume, assessed by preoperative MRI, was comparable between patients with and without preoperative embolization (p = .14). Surgeries without embolization had a mean intraoperative blood loss of 3250 ml, erythrocyte transfusion volume of 1125 ml, and a mean surgical time of 114.5 min for two surgeries. Surgeries with preoperative embolization showed a mean intraoperative blood loss of 1850 ml, no erythrocyte transfusion requirement, and a mean surgical time of 68 min., Conclusion: Curettage of GCTB in the posterior pelvis and sacrum presents challenges, with significant intraoperative blood loss impacting surgical time and transfusion needs. Preoperative embolization may be beneficial in reducing blood loss during surgery in these cases., Competing Interests: Declaration of competing interest None of the authors declare any conflict of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Rate of evolution on imaging of a benign primary bone tumour - giant cell tumour.
- Author
-
Murphy GT, Shatz J, Bonar SF, Mahar A, and Boyle R
- Subjects
- Humans, Magnetic Resonance Imaging methods, Female, Male, Tomography, X-Ray Computed methods, Adult, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms diagnostic imaging, Bone Neoplasms pathology
- Published
- 2024
- Full Text
- View/download PDF
7. Periprosthetic giant cell tumour of the tibia: en bloc resection and megaprosthesis revision.
- Author
-
Panos A, Agathangelidis F, Givissis P, and Samoladas E
- Subjects
- Humans, Female, Aged, Prosthesis Failure, Tibia surgery, Tibia pathology, Tibia diagnostic imaging, Arthroplasty, Replacement, Knee methods, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone diagnostic imaging, Bone Neoplasms surgery, Bone Neoplasms pathology, Reoperation, Knee Prosthesis
- Abstract
We present a case detailing the diagnosis and management of a periprosthetic giant cell tumour in a female patient in her 70s, who had undergone total knee arthroplasty (TKA) for primary osteoarthritis in her right knee 7 years prior. The patient reported 4 months of painful weight-bearing. Various imaging modalities, including plain radiographs, CT scans and MRI, revealed a sizeable lytic lesion beneath the TKA prosthesis, along with loosening of the tibial component.Blood tests and analyses of synovial fluid ruled out periprosthetic joint infection, and a biopsy confirmed the diagnosis of a giant cell tumour of the bone. Treatment entailed en bloc resection of the tumour and revision of the TKA using a hinged, oncological-type megaprosthesis. Surgical procedures involved careful resection of the proximal tibia, preservation of vasculature and the creation of a medial gastrocnemius muscle flap. Following surgery, the patient underwent supervised rehabilitation with a functional brace., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
8. En bloc resection and iliac crest bone grafting for giant cell tumor of the finger.
- Author
-
Saleh J, Tremblay D, and Boghossian E
- Subjects
- Humans, Male, Arthrodesis, Adult, Female, Ilium transplantation, Giant Cell Tumor of Bone surgery, Bone Neoplasms surgery, Finger Phalanges surgery, Bone Transplantation methods
- Abstract
A case of a rapidly progressing giant cell tumor of the middle phalanx is presented. The patient underwent en bloc resection with iliac crest grafting and distal interphalangeal fusion. Surgical technique and patient's functional outcomes are described., (Crown Copyright © 2024. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
- Author
-
Al Farii H, McChesney G, Patel SS, Rhines LD, Lewis VO, and Bird JE
- Subjects
- Humans, Bone Density Conservation Agents therapeutic use, Spinal Cord Compression etiology, Spinal Cord Compression surgery, Spinal Cord Compression drug therapy, Adult, Male, Female, Thoracic Vertebrae surgery, Thoracic Vertebrae pathology, Middle Aged, Denosumab therapeutic use, Spinal Neoplasms drug therapy, Spinal Neoplasms surgery, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone surgery, Neoadjuvant Therapy
- Abstract
Background Context: Giant cell tumor (GCT) of bone is most commonly a benign but locally aggressive primary bone tumor. Spinal GCTs account for 2.7% to 6.5% of all GCTs in bone. En bloc resection, which is the preferred treatment for GCT of the spine, may not always be feasible due to the location, extent of the tumor, and/or the patient's comorbidities. Neoadjuvant denosumab has recently been shown to be effective in downstaging GCT, decreasing the size and extent of GCTs. However, the risk of neurologic deterioration is of major concern for patients with epidural spinal cord compression due to spinal GCT. We experienced this concern when a patient presented to our institution with a midthoracic spinal GCT with progressive epidural disease. The patient was not a good surgical candidate due to severe cardiac disease and uncontrolled diabetes. In considering nonoperative management for this patient, we asked ourselves the following question: What is the risk that this patient will develop neurologic deterioration if we do not urgently operate and opt to treat him with denosumab instead?, Purpose: The purpose of this study was to assess the literature to (1) determine the risk of neurological deterioration in patients receiving neoadjuvant denosumab for the treatment of spinal GCT and (2) to evaluate the secondary outcomes including radiographic features, surgical/technical complexity, and histological features after treatment., Study Design/setting: Meta-analysis of the literature., Patient Sample: Surgical cases of spinal GCT that (1) presented with type III Campanacci lesions, (2) had epidural disease classified as Bilsky type 1B or above and (3) received neoadjuvant denosumab therapy., Outcome Measures: The primary outcome measure of interest was neurologic status during denosumab treatment. Secondary outcome measures of interest included radiographic features, surgical/technical complexity, histological features, tumor recurrence, and metastasis., Methods: Using predetermined inclusion and exclusion criteria, PubMed and Embase electronic databases were searched in August 2022 for articles reporting spinal GCTs treated with neoadjuvant denosumab and surgery. Keywords used were "Spine" AND "Giant Cell Tumor" AND "Denosumab.", Results: A total of 428 articles were identified and screened. A total of 22 patients from 12 studies were included for review. 17 patients were female (17/22, 77%), mean age was 32 years (18-62 years) and average follow-up was 21 months. Most GCTs occurred in the thoracic and thoracolumbar spine (11 patients, 50%), followed by 36% in the lumbar spine and 14% in the cervical spine. Almost half of the patients had neurological deficits at presentation (10/22 patients, 45%), and more than 60% had Bilsky 2 or 3 epidural spinal cord compression. None of the patients deteriorated neurologically, irrespective of their neurological status at presentation (p-value=.02, CI -2.58 to -0.18). There were no local recurrences reported. One patient was found to have lung nodules postoperatively. More than 90% of cases had decreased overall tumor size and increased bone formation. Surgical dissection was facilitated in more than 85% of those who had documented surgical procedures. Four patients (18%) underwent initial spinal stabilization followed by neoadjuvant denosumab and then surgical excision of the GCT. Regarding the histologic analyses, denosumab eradicated the giant cells in 95% of cases. However, residual Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL)-positive stromal cells were noted, in 27% (6 cases)., Conclusions: Neoadjuvant denosumab was a safe and effective means of treating spinal GCTs prior to surgery. Neurologic status remained stable or improved in all cases included in our review, irrespective of the presenting neurologic status. The most appropriate dosage and duration of denosumab therapy is yet to be determined. We recommend future well-designed studies to further evaluate the use of neoadjuvant denosumab for patients with spinal GCT., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Multifocal Giant Cell Tumor of the Nasal Fossa: Case Report and Literature Review.
- Author
-
Serafini E, Basso M, Melchiorri C, Di Massa G, Lupi M, Alicandri-Ciufelli M, and Marchioni D
- Subjects
- Humans, Male, Female, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone diagnosis, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone diagnostic imaging, Adult, Tomography, X-Ray Computed, Diagnosis, Differential, Middle Aged, Nose Neoplasms surgery, Nose Neoplasms pathology, Nose Neoplasms diagnosis, Nasal Cavity surgery, Nasal Cavity pathology, Nasal Cavity diagnostic imaging
- Abstract
Giant cell tumors of bone (GCT) are rare soft tissue tumors, that account for 3%-5% of primary bone tumors with <2% occurring in the head and neck. The nasal cavity is a highly unusual site of presentation. We reviewed 15 cases of GCT of nasal cavity and paranasal sinuses. We add 1 case to the literature. The case herein reported, appears to be the second nasal fossa GCT described in the literature and the first documented case with multifocal localization. A case of multifocal GCT of the nasal cavity is described. Although rare in the general population, GCT should be included among the possibilities in the differential diagnosis when evaluating tumors of the head and neck. Management of this particular tumor remains challenging; surgical removal is still the gold standard treatment, preferring a minimally invasive trans-nasal approach to reduce intra and post-operative morbidity. Laryngoscope, 134:2774-2778, 2024., (© 2023 The Authors. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
11. Diaphyseal giant cell tumour of mid-shaft tibia.
- Author
-
Kantiwal P, Suhail A, Rao M, and Gahlot N
- Subjects
- Humans, Female, Curettage, Bone Transplantation methods, Middle Aged, Ilium diagnostic imaging, Fibula diagnostic imaging, Fibula pathology, Fibula surgery, Diaphyses surgery, Treatment Outcome, Tibia diagnostic imaging, Tibia surgery, Tibia pathology, Bone Neoplasms surgery, Bone Neoplasms pathology, Bone Neoplasms diagnostic imaging, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone diagnostic imaging
- Abstract
SummaryGiant cell tumours of bone are benign and locally aggressive tumours that usually occur in young adults and at the epiphysial locations after physeal closure. Occurrence outside of epiphysial locations and appearance in geriatric patients is rare. We report a case of a woman in her late 60s with a giant cell tumour of the mid-shaft of the right tibia. Extended curettage and biological reconstruction were performed with autologous double-barrel fibular struts and tri-cortical iliac crest bone grafting. At the 28-month follow-up examination, we noted full bony union at both ends with successful consolidation of the fibular struts, and importantly, no evidence of recurrence or other complications was observed., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
12. Reconstruction of the extensor mechanism using polypropylene mesh in a displaced pathological fracture of the patella affected by giant cell tumour.
- Author
-
Tripathy S, Khan S, Patel H, and Pradhan SS
- Subjects
- Humans, Male, Adult, Giant Cell Tumor of Bone surgery, Fractures, Spontaneous surgery, Fractures, Spontaneous etiology, Fractures, Spontaneous diagnostic imaging, Plastic Surgery Procedures methods, Treatment Outcome, Surgical Mesh, Patella surgery, Patella injuries, Patella diagnostic imaging, Bone Neoplasms surgery, Bone Neoplasms complications, Polypropylenes
- Abstract
A man in his 30s came to our clinic with a year-long history of progressive pain and swelling in his knee. Diagnostic imaging revealed a displaced patellar fracture with an osteolytic, septated lesion and thinned expanded cortex in both fracture fragments. A core needle biopsy confirmed the diagnosis of giant cell tumour. Treatment involved wide excision of the tumour and the use of polypropylene mesh and a peroneal longus tendon autograft to reconstruct the extensor mechanism of the knee joint. One year postoperatively, the patient experienced no pain, demonstrated full range of motion and showed no signs of functional impairment or local tumour recurrence. This case highlights that reconstruction of the extensor mechanism of the knee after tumour excision with synthetic mesh is an affordable, user-friendly and widely accessible method. It can address large defects effectively while minimising the risks of disease transmission and graft lengthening, resulting in satisfactory outcomes., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
13. Intralesional curettage and surgical adjuvants in the treatment of giant cell tumor of bone: meta-analysis and systematic review.
- Author
-
Leng A, Gao H, Li J, Meng L, Wang Q, and Xiang L
- Subjects
- Humans, Giant Cell Tumor of Bone surgery, Curettage methods, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
Background: The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. Various surgical adjuvants have been introduced following intralesional curettage to improve local control rates. However, findings from relevant studies are inconsistent, and no consensus has been reached. The purpose of this study is to determine what intraoperative adjuvant is effective in decreasing the recurrence of GCTB., Methods: We performed a systematic review and meta-analysis of articles published in the PubMed and Embase electronic databases which assessed the recurrence rate of GCTB following intralesional curettage with or without various surgical adjuvants. Two authors independently evaluated all publications. Meta-analysis was performed with Stata/MP (Version 17.0, StataCorp LLC, TX, USA) and Review Manager (RevMan, Version 5.4.1, The Cochrane Collaboration, 2020). Pooled risk ratio (RR) was used for analysis, with P values less than 0.05 considered statistically significant., Results: Twenty-four studies involving 2,579 patients were included in this analysis. The overall recurrence rates for patients treated with or without high-speed burring (HSB) are 11.9% (26/218) and 47.7% (92/193), respectively. The pooled RR for tumor recurrence is 0.33 (95% CI: 0.22 to 0.49, P<0.001). In the meanwhile, the overall recurrence rates for patients treated with or without chemical adjuvants are 23.5% (77/328) and 26.1% (73/280), respectively, with a pooled RR of 0.84 (95% CI: 0.63 to 1.10, P=0.89). Additionally, the overall recurrence rates for patients treated with or without polymethyl methacrylate (PMMA) are 20.4% (205/1,006) and 33.4% (314/939), respectively, with a pooled RR of 0.59 (95% CI: 0.50 to 0.69, P<0.001)., Conclusions: Intraoperative application of HSB or PMMA has an additional antitumor effect, while the use of phenol or H2O2 fails to make any significant difference (PROSPERO: CRD42022344262).
- Published
- 2024
- Full Text
- View/download PDF
14. Non-vascularized toe phalangeal transfer for reconstruction of a giant cell tumour of the proximal phalanx.
- Author
-
Jerome JTJ and Ravi M
- Subjects
- Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Toe Phalanges transplantation, Toes surgery, Giant Cell Tumor of Bone surgery, Bone Neoplasms surgery
- Abstract
This article describes a 50-year-old woman with a giant cell tumour involving the base of the proximal phalanx, which was resected and reconstructed with a non-vascularised toe phalanx graft. The toe phalanx graft united well, and there was no tumour recurrence at the 24-month follow-up., Competing Interests: Declaration of conflicting interestsThe authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
15. Malignant giant cell tumour of distal ulna.
- Author
-
Yadav SK, Rajnish RK, Prakash V, and Nalwa A
- Subjects
- Humans, Ulna diagnostic imaging, Ulna surgery, Upper Extremity pathology, Neoplasm Recurrence, Local pathology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms diagnostic imaging, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
Giant cell tumour (GCT) accounts for 5% of all primary bone tumours. GCT in the distal third of ulna is quite rare. We present a case of recurrent GCT in distal third of ulna with malignant features involving tenosynovium. The case was treated by wide resection of tumour and on follow up, patient recovered well with no evidence of further recurrence. Considering the features, according to the literature reviewed, is the first case of its type., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
16. Functional Outcomes of Centralization of the Ulna as a Method of Reconstruction Following Resection of Campanacci Grade 3 Giant Cell Tumor of the Distal Radius.
- Author
-
Kapoor L, Banjara R, Sahoo B, Kumar VS, Ansari MT, and Khan SA
- Subjects
- Humans, Radius surgery, Radius pathology, Hand Strength, Treatment Outcome, Ulna, Wrist Joint diagnostic imaging, Wrist Joint surgery, Wrist Joint pathology, Retrospective Studies, Range of Motion, Articular, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Bone Neoplasms diagnostic imaging, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
Purpose: Wrist reconstruction after distal radial tumor resection poses a challenge to the orthopedic oncologist. We evaluated the functional outcomes of centralization of the ulna with ulnocarpal arthrodesis as a method of reconstruction following resection of distal radius tumors, using impairment measures and patient-reported outcomes., Methods: Evaluation of functional outcome was performed using the Musculoskeletal Tumor Society 93 scoring system and Disabilities of the Arm, Shoulder, and Hand questionnaire. We also determined hand grip strength on the affected side, time to radiologic union at the ulnocarpal junction and reduction in wrist circumference. Local complications and oncologic outcomes were recorded., Results: The study included 26 patients with Campanacci grade 3 giant cell tumor of the distal radius. Mean follow-up period in the study was 32.8 ± 12 months. Mean resection length was 10.3 ± 2.5 cm. Radiologic union at the ulnocarpal junction was achieved in 38.5%, 77% and 96% of the patients by 4, 5, and 6 months respectively. Mean hand grip strength was 74 ± 3.9% of the contralateral side whereas mean reduction in wrist circumference was 16.9 ± 6.4%. A good functional outcome with a mean the Musculoskeletal Tumor Society 93 score of 26 ± 1.4 and mean Disabilities of the Arm, Shoulder, and Hand score of 10.5 ± 6.3 was observed. Fracture of the ulna, hardware loosening, and reflex sympathetic dystrophy were each noted in 1 patient, with an overall complication rate of 10.7% (3/28). No patient had nonunion, infection, or local recurrence., Conclusions: This is a simple and effective modality of reconstruction after resection of distal radial tumors. It provides good functional outcome and preservation of good hand grip strength, with low complication rates., Type of Study/level of Evidence: Therapeutic IV., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
17. Giant Cell Tumor of the Acromion: Case Report and Literature Review.
- Author
-
Sano J, Chijiiwa Y, and Nishio J
- Subjects
- Female, Middle Aged, Young Adult, Humans, Adult, Acromion diagnostic imaging, Acromion surgery, Acromion pathology, Shoulder Pain diagnosis, Shoulder Pain etiology, Radiography, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone diagnostic imaging, Bone Neoplasms diagnostic imaging, Bone Neoplasms pathology
- Abstract
Background/aim: Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm that typically occurs in the ends (epiphyses) of long bones of young adults. Flat bones are uncommon sites of involvement. Herein, we describe an unusual case of pathologically proven GCT of the acromion., Case Report: The patient was a 39-year-old woman with no history of trauma who presented with a 3-month history of right posterior shoulder pain. Physical examination revealed mild swelling and tenderness in the posterior aspect of the right shoulder. Plain radiograph showed a purely lytic lesion, suggestive of a bone tumor. Computed tomography demonstrated an intraosseous lytic lesion with associated cortical thinning and lack of periosteal reaction. On magnetic resonance imaging, the lesion exhibited slightly higher signal intensity compared to skeletal muscle on T1-weighted sequences and heterogeneous high signal intensity on T2-weighted sequences. Strong enhancement was observed following gadolinium administration. The lesion was treated by extensive curettage with adjuvant therapy comprising ethanol and the remaining cavity was filled with polymethylmethacrylate bone cement. Histologically, the lesion was composed of round or spindle-shaped mononuclear cells admixed with numerous osteoclast-like giant cells. Immunohistochemically, the mononuclear neoplastic cells were diffusely positive for H3.3 G34W. The patient was asymptomatic and there was no evidence of local recurrence or distant metastasis 5 months after surgery., Conclusion: Although rare, acromial GCTB should be considered in the differential diagnosis of posterior shoulder pain, especially in young and early middle-aged adults., (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Denosumab for an inoperable giant cell tumour of the ischial bone.
- Author
-
Paul AG, See LP, Ohn MH, and Ohn KM
- Subjects
- Female, Humans, Denosumab therapeutic use, Biopsy, Bone Neoplasms diagnostic imaging, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Bone Density Conservation Agents therapeutic use, Spinal Neoplasms pathology
- Abstract
Giant cell tumour of bone is a benign, locally aggressive osteolytic tumour that typically affects skeletally mature young individuals. It predominantly emerges within the metaphysis, extending towards the epiphysis of long bones, while occurrences in flat bones are exceptionally rare. We present a case of a woman in her late 20s who presented with a large right ischial mass. A biopsy confirmed the mass as a giant cell tumour. The tumour extended to the acetabulum, and due to the potential risk of significant bleeding and contamination during en bloc excision, a prudent approach involved initiating denosumab therapy, a monoclonal antibody targeting receptor activator of nuclear factor-κB ligand therapy, before proceeding with radical surgery. Denosumab therapy successfully rendered a previously inoperable tumour favourable for surgical intervention. We went on to perform a type 2 and 3 internal hemipelvectomy, followed by a reconstruction with a hip endoprosthesis replacement., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
19. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
- Author
-
Tang Q, Lu J, Zhu X, Song G, Wu H, Xu H, Wang A, and Wang J
- Subjects
- Humans, Denosumab adverse effects, Neoadjuvant Therapy, Treatment Outcome, Retrospective Studies, Neoplasm Recurrence, Local surgery, Bone Density Conservation Agents therapeutic use, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Bone Neoplasms diagnostic imaging, Bone Neoplasms drug therapy, Bone Neoplasms surgery
- Abstract
Purpose: This study aimed to investigate whether short course of neoadjuvant denosumab treatment for spinal GCTB could (1) Induce radiological and histological response? (2) Facilitate en bloc resection? (3) Achieve satisfactory oncological and functional outcomes?, Methods: The clinical information of ten consecutive patients between 2018 and 2022 with spinal GCTB treated with short course of neoadjuvant denosumab (≤ 5 doses) and en bloc spondylectomy was retrospectively reviewed. The radiological and histological response, operative data, oncological and functional outcomes were analyzed., Results: The mean doses of neoadjuvant denosumab were 4.2 (range 3-5 doses). After neoadjuvant denosumab, there were 9 cases showing new ossification and 5 cases with reappearance of cortical integrity. The values of Hounsfield units (HU) of the soft tissue component were increased by > 50% in 7 cases. The signal intensity (SI) ratios of tumor/muscle in T2WI of plain MRI were decreased by > 10% in 60% of the cases. Shrinkage of soft tissue mass by > 10% was observed in 4 cases. The mean duration of operation was 575 ± 174 min, and the mean estimated blood loss (EBL) was 2790 ± 1934 ml. No obvious adhesion to dura mater or major vessels was encounter intraoperatively. There is no tumor collapse or breakage during surgery. Multinucleated giant cells were decreased in 6 cases (60%) with the remaining 4 cases showing absence of multinucleated giant cells. Mononuclear stromal cells existed in most of the cases (8 cases, 80%). New bone formation was noticed in 8 cases (80%). No patient had a worsening of neurologic function after surgery. No tumor recurrence was noticed within the mean follow-up of 24 ± 20 months., Conclusion: Short-term neoadjuvant denosumab could yield radiological and histological responses and might facilitate en bloc spondylectomy by hardening the tumor and causing less adhesion to segmental vessels, major vessels and nerve roots, which was beneficial to achieve the optimal oncological and functional outcomes., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
20. Multicentric Giant Cell Tumor of Bone.
- Author
-
Errani C, Tsukamoto S, Angulo Alvarado R, Righi A, Nitta Y, Donati DM, and Mavrogenis AF
- Subjects
- Humans, Curettage, Neoplasm Recurrence, Local surgery, Retrospective Studies, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms diagnostic imaging, Bone Neoplasms surgery, Orthopedic Procedures
- Abstract
The typical presentation of giant cell tumor of bone is a solitary lesion involving the meta-epiphyseal region of the long bones. The presence of more than one distinct giant cell tumor in the same patient is rare. This study reports on 7 patients with multicentric giant cell tumor of bone. Clinical and radiologic features were reviewed to evaluate the behavior of multicentric giant cell tumor of bone. Immunohistochemistry and genetic analysis for the H3F3A gene were performed to confirm the diagnosis. The knee was most frequently involved, and most of the lesions were in an ipsilateral extremity. All of the patients received surgical management with curettage or resection. The overall median follow-up was 194 months (interquartile range, 41-336 months). Five of 7 patients had local recurrence (71%), but considering the number of surgically treated lesions, the risk of local recurrence was 33% (5 local recurrences among 15 treated lesions). No lung metastases occurred. Multicentric giant cell tumor of bone tends to exhibit the same aggressive clinical behavior as solitary giant cell tumor of bone. Patients should be monitored for the occurrence of other lesions, especially in the ipsilateral extremity. [ Orthopedics . 2023;46(6):e376-e380.].
- Published
- 2023
- Full Text
- View/download PDF
21. Malignant transformation of metastatic giant cell tumor of bone in a patient undergoing denosumab treatment: A case report.
- Author
-
Yung D, Asano N, Hirozane T, Yamaguchi S, Mori T, Susa M, Okita H, Morioka H, Horiuchi K, and Nakayama R
- Subjects
- Humans, Denosumab therapeutic use, Bone and Bones pathology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Bone Density Conservation Agents adverse effects, Bone Neoplasms drug therapy, Bone Neoplasms pathology
- Abstract
Competing Interests: Declaration of competing interest The authors declare that they have no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
22. Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review.
- Author
-
Sereno M, Franco SR, de la Reina L, Campo-Cañaveral de la Cruz JL, Muñoz de Legaría M, and Casado Saénz E
- Subjects
- Humans, Denosumab therapeutic use, Neoadjuvant Therapy, Giant Cells pathology, Bone Density Conservation Agents therapeutic use, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Spinal Neoplasms drug therapy, Spinal Neoplasms pathology
- Abstract
Giant cell tumors of bone are a rare entity, usually occurring in young patients and characteristically arising in the long bones. The spinal location is rare and usually presents with pain and/or neurological symptoms. The treatment of choice is surgery. Treatment with Denosumab, a bisphosphonate inhibitor of RANK-L, which is highly expressed in these tumors, has shown extensive activity in unresectable patients or those undergoing incomplete surgery. Preoperative treatment with this drug is gaining increasing interest, as its high potency in tumor reduction in this subtype of neoplasm has allowed resectability in selected patients. We present the case of a young patient with a large spinal tumor who, after neoadjuvant Denosumab, underwent complete en bloc surgery with clean margins and a great pathological response.
- Published
- 2023
- Full Text
- View/download PDF
23. Giant Cell Tumor of the Temporal Bone and Skull Base.
- Author
-
Amoodi H, Al-Domaidat D, Danish A, and Alshaikh Hasan R
- Subjects
- Female, Humans, Adult, Skull Base pathology, Temporal Bone diagnostic imaging, Temporal Bone pathology, Cranial Fossa, Middle diagnostic imaging, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Skull Base Neoplasms diagnostic imaging, Skull Base Neoplasms surgery
- Abstract
Giant cell tumor (GCT) is a benign tumor that originates from undifferentiated mesenchymal cells of the bone marrow. The craniums as well as temporal bone are extremely rare locations for GCTs. Clinical, radiological, and anatomical diagnosis of this locally aggressive disease poses a major challenge in clinical practice. In this article, we present a clinical study for a 35-year-old female who was found to have left-sided temporal bone GCT with extension to middle cranial fossa and temporomandibular joint (TMJ) with its clinical features and management., Competing Interests: The authors report no conflicts of interest., (Copyright © 2023 by Mutaz B. Habal, MD.)
- Published
- 2023
- Full Text
- View/download PDF
24. Heat treatment for giant cell tumors of bone: A systematic review.
- Author
-
Schoutens C and Verspoor FG
- Subjects
- Humans, Retrospective Studies, Argon, Hot Temperature, Quality of Life, Curettage adverse effects, Pain etiology, Neoplasm Recurrence, Local surgery, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
This systematic review evaluates the effects of heat treatments in de novo, residual and recurrent giant cell tumors of bone (GCTB). Studies were eligible for inclusion if one of the following treatments was administered: radiofrequency ablation (RFA), microwave ablation, argon cauterization, electrocauterization and hot liquid treatment. The primary outcome was recurrence. Secondary outcomes were complications, pain, function, and quality of life. Recurrence rates for microwave ablation as an adjuvant to intralesional curettage were 0%, 4% and 10% (3 retrospective single-group studies); for argon cauterization 4%, 8% and 26% (3 cohort studies); electrocauterization 0% to 33% (8 cohort studies); and hot liquid 9.5% and 24% (2 cohort studies). Follow-up was generally ≥24 months. Data on pain, function and quality of life were scarce. Complications included infection and secondary osteoarthritis. Current evidence does not demonstrate or exclude an effect of heat treatments on recurrence in GCTB. Further research should objectify if (subgroups of) patients benefit from these treatments.
- Published
- 2023
- Full Text
- View/download PDF
25. Treatment of pelvic giant cell tumor by wide resection with patient-specific bone-cutting guide and reconstruction with 3D-printed personalized implant.
- Author
-
Li Z, Lu M, Min L, Luo Y, and Tu C
- Subjects
- Adult, Female, Humans, Male, Printing, Three-Dimensional, Prostheses and Implants, Retrospective Studies, Plastic Surgery Procedures, Surgical Wound surgery, Pelvic Bones surgery, Giant Cell Tumor of Bone surgery, Bone Neoplasms surgery
- Abstract
Background: This study reports our experience in the treatment of aggressive pelvic GCT through wide resection assisted with patient-specific bone-cutting guides (PSBCGs) and subsequent reconstruction with 3D-printed personalized implants (3DPIs), aiming to present the operative technique of this method and evaluate its clinical efficacy., Methods: We retrospectively analyzed seven patients who underwent wide resection of pelvic GCT followed by reconstruction with 3DPIs from August 2019 to February 2021. There were two males and five females, with a mean age of 43 years. PSBCGs and 3DPIs were prepared using 3D-printing technology. The operational outcomes, local recurrence, radiological results, and any associated complications of this technique were assessed. And the functional outcomes were assessed according to the Musculoskeletal Tumor Society (MSTS) 93 functional score., Results: The mean follow-up time was 35.3 months (range 28-45 months). There was no intraoperative complication. Negative surgical margins were achieved in all patients. Postoperative pelvic radiographs showed that 3DPIs matched the shape and size of the bone defect. The anterior-posterior, inlet, and outlet pelvic radiograph demonstrated precise reconstruction consistent with the surgical planning. In addition, tomosynthesis-Shimadzu metal artifact reduction technology (T-SMART) showed good osseointegration at an average of three months after surgery (range 2-4 months). There was no local recurrence or tumor metastasis. The average MSTS score was 24.4 (range 23-27) at the last follow-up. Delayed wound healing was observed in one patient, and the wounds healed after debridement. Prosthesis-related complications were not detected during the follow-up, such as aseptic loosening or structure failure., Conclusions: The treatment of aggressive pelvic GCTs through wide resection assisted with PSBCGs and subsequent reconstruction with 3DPIs is a feasible method, which provides good clinical results and reasonable functional outcomes., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
26. The Role of Denosumab in the Treatment of Primary Tumors of Bone.
- Author
-
Wessel LE, Strike SA, Singh A, Bernthal NM, and Athanasian EA
- Subjects
- Humans, Denosumab therapeutic use, Bone and Bones, Bone Density Conservation Agents therapeutic use, Giant Cell Tumor of Bone surgery, Bone Neoplasms pathology
- Abstract
Many hand surgeons treat benign bone tumors without referral to orthopedic oncologists. However, there have been considerable advances in medical therapy for some of these tumors, with which hand surgeons may not be as familiar. This review focuses on the mechanism and uses of denosumab in the treatment of benign tumors of bone. Although the hand surgeon may not be directly prescribing this therapy, they are often the only physician treating the patient for these conditions. As such, awareness regarding the use of this therapy in reducing pain, decreasing tumor volume, and treatment of potential lung metastases is critical to those taking on these cases without the support of an orthopedic oncologist. This article aims to familiarize hand surgeons with denosumab to help promote knowledge of this therapeutic option and the potential role of this medication in the treatment of primary bone tumors in the hand., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
27. Recurrent Giant Cell Tumor of Bone with New Pulmonary Metastases 9 Years After En Bloc Distal Radius Resection: A Case Report.
- Author
-
DeFazio MW, Selove W, Watts G, Harchandani S, Sood R, Lou F, and Most MJ
- Subjects
- Male, Humans, Adult, Radius surgery, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Lung Neoplasms surgery, Bone Neoplasms diagnostic imaging, Bone Neoplasms surgery
- Abstract
Case: A 31-year-old man with a history of giant cell tumor of bone (GCTB) in the distal radius presents to clinic 9 years after en bloc distal radius resection. He was found to have a new soft tissue mass consistent with GCTB and new pulmonary metastases. Ultimately, he underwent excision of his soft tissue recurrence and partial lobectomy for his lung metastases., Conclusion: This case highlights the importance of having a high level of suspicion for local recurrence or metastasis, even years after wide resection and negative margins., Competing Interests: Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSCC/C185)., (Copyright © 2023 by The Journal of Bone and Joint Surgery, Incorporated.)
- Published
- 2023
- Full Text
- View/download PDF
28. Giant cell tumor of bone with secondary aneurysmal bone cyst does not have a higher risk of local recurrence.
- Author
-
Tsukamoto S, Aiba H, Righi A, Nitta Y, Traversari M, Mavrogenis AF, Honoki K, Tanaka Y, Donati DM, and Errani C
- Subjects
- Humans, Neoplasm Recurrence, Local pathology, Bone and Bones pathology, Bone Cysts, Aneurysmal diagnostic imaging, Bone Cysts, Aneurysmal surgery, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Bone Neoplasms complications, Bone Neoplasms diagnostic imaging, Bone Neoplasms surgery
- Abstract
Background: Fluid-fluid levels (FFLs) is found in 10%-16% of giant cell tumor of bone (GCTB), and the presence of FFLs raises the suspicion of GCTB with secondary aneurysmal bone cyst (ABC), which can lead to increased intraoperative bleeding and, blurring the operative field, be associated with a risk of local recurrence. The first objective of this study is to determine whether secondary ABC is associated with a higher risk of local recurrence after curettage in patients with GCTB of the extremities. The second objective of this study is to investigate the sensitivity, specificity, positive predictive value, and negative predictive value of the presence of FFLs detected on magnetic resonance imaging (MRI) to diagnose secondary ABC associated with GCTB., Methods: Two hundred and eighty patients with GCTB of the extremities who underwent curettage at the authors' institutions between 1980 and 2021 were included in this study., Results: Secondary ABC was found in 36 of 280 patients (12.9%) and local recurrence occurred in 66 of 280 patients (23.6%). Multivariate analysis showed no significant correlation between secondary ABC and local recurrence (hazard ratio [HR]: 1.87 (95% confidence interval [CI]: 1.00-3.53]; p = 0.051). Preoperative MRI revealed FFLs in 13 of 82 patients (15.9%). Sensitivity, specificity, positive predictive value, and negative predictive value of FFLs detected on preoperative MRI to diagnose secondary ABC were 36.8%, 90.5%, 53.8%, and 82.6%, respectively., Conclusion: The results of this study showed that secondary ABC does not increase the risk of local recurrence after curettage in patients with GCTB of the extremities. Although rare, FFLs were present in patients with GCTB and half of those with FFLs detected on preoperative MRI had secondary ABC., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
29. Microwave in situ inactivation in the treatment of bone giant cell tumor: a mid-term descriptive study.
- Author
-
Jiang X, Chen J, Zhou W, Zhang C, Wang G, Dong D, Xia P, Liu X, and Xu F
- Subjects
- Humans, Polymethyl Methacrylate, Retrospective Studies, Microwaves therapeutic use, Treatment Outcome, Neoplasm Recurrence, Local, Bone Neoplasms surgery, Bone Neoplasms pathology, Giant Cell Tumor of Bone radiotherapy, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone complications
- Abstract
Aim: To evaluate the mid-term clinical efficacy of microwave in situ inactivation combined with bone grafting or polymethyl methacrylate (PMMA) filling in the treatment of giant cell tumor of bone (GCTB)., Methods: This is a retrospective, descriptive, and analytical study. A total of 30 GCTB patients received microwave in situ inactivation from January 2012 to January 2020, whose clinical recurrence rate was evaluated at the last follow-up after microwave in situ inactivation surgery. The Musculoskeletal Tumor Society (MSTS) function score was used to evaluate the postoperative clinical panoramic results., Results: All patients were followed up for 21 to 110 months, with an average of 63.79 months. Distal femur (40%) and proximal tibia (28%) had a higher rate of GCTB incidence. Seventeen percent of tumor patients suffered from associated pathologic fracture. The rate of Campanacci classification stage III was 60%. The average MSTS score was evaluated as 27.53 points overall at the last follow-up. In terms of complications, three, two, two and one cases developed fat liquefaction, controllable tissue rejection reaction, incision infection and degenerative changes around lesion joint, respectively, without in situ recurrences and reoperation as well as distant lung metastasis., Conclusions: The method of microwave in situ inactivation combined with bone grafting or PMMA filling is prudently recommended as one of the options for the limb salvage treatment of giant cell tumor of long and periarticular bone., Level of Evidence: IV: case series., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
30. An improved total en bloc spondylectomy for L5 vertebral giant cell tumor through a single-stage posterior approach.
- Author
-
Wan W, Zheng W, Wan J, Zhang J, Liu Y, Jia Q, Zhong N, Zhao J, Yang M, Yang X, and Xiao J
- Subjects
- Humans, Denosumab, Neoplasm Recurrence, Local surgery, Lumbar Vertebrae surgery, Lumbar Vertebrae pathology, Diphosphonates, Treatment Outcome, Spinal Neoplasms diagnostic imaging, Spinal Neoplasms surgery, Spinal Neoplasms pathology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology
- Abstract
Purpose: Although total en bloc spondylectomy (TES) is strongly recommended for spinal giant cell tumor (GCT), it is extremely difficult to excise a L5 neoplasm intactly through the single-stage posterior approach. Given the risk of neurological and vascular injury, intralesional curettage (IC) is usually recommended for the treatment of L5 GCT. In this study, we presented our experience with the use of an improved TES to treat L5 GCT through the single-stage posterior approach., Methods: This study included 20 patients with L5 GCT who received surgical treatment in our department between September 2010 and April 2021. Of them, seven patients received improved TES without iliac osteotomy, and the other 13 patients received IC (n = 8), sagittal en bloc resection (n = 1), TES with iliac osteotomy (n = 3), and TES with radicotomy (n = 1) as control., Results: The mean operative time was 331.43 ± 92.95 min for improved TES group and 365.77 ± 85.17 min for the control group (p = 0.415), with the mean blood loss of 1142.86 ± 340.87 ml vs. 1969.23 ± 563.30 ml (p = 0.002). Postoperative treatment included bisphosphonates in nine patients and denosumab in 12 patients including one patient who changed from bisphosphonates to denosumab. Three patients who received IC experienced local recurrence, and no relapse was observed in improved TES group., Conclusion: Single-stage posterior TES for L5 GCT was previously considered impossible. In this study, we presented our experience with the use of an improved surgical technique for L5 TES through the single-stage posterior approach, which has proved to be superior to the conventional procedures in terms of blood loss control and complication and recurrence rates., Level of Evidence: IV., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
31. Primary Cooperative Application of a LARS® Tube and 3D-Printed Prosthesis for Reconstruction of the Distal Radius after en bloc Resection of Giant Cell Tumor of Bone: A Comparative Retrospective Study.
- Author
-
Shao X, Ding H, Li J, Lv Z, Yang Q, Chu Q, Li K, and Li Z
- Subjects
- Humans, Radius surgery, Retrospective Studies, Follow-Up Studies, Treatment Outcome, Wrist Joint surgery, Prostheses and Implants, Printing, Three-Dimensional, Range of Motion, Articular, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
Objective: Using a fibula autograft (FA) to reconstruct defects after en bloc resection of giant cell tumor of bone (GCTB) in the distal radius is classic but has high complication rates. We describe a novel reconstruction method employing the cooperative application of LARS® and a 3D-printed prosthesis (L-P) and investigate whether it improves postoperative outcomes., Methods: From April 2015 to August 2022, 14 patients who underwent the cooperative L-P reconstruction method after en bloc resection of distal radial GCTBs and 31 patients who received FA reconstruction were enrolled as two retrospective cohorts in this comparative study. The properties of the implants and critical surgical techniques were elaborated in the L-P group. Preoperative function, intraoperative data, and postoperative clinical, functional, and radiographic outcomes of all patients were recorded and compared between the two groups. The grip strength and range of wrist motion, including extension, flexion, radial deviation, and ulnar deviation, were measured. The Mayo modified wrist and Musculoskeletal Tumor Society scores were chosen to assess wrist function and surgical functional outcomes, respectively. Kaplan-Meier curves were generated to analyze the significant differences in complication rates and implant survival between the two groups., Results: In both groups, all 45 patients underwent the operation without complication with similar average osteotomy lengths and bleeding volumes, while a shorter operative duration was achieved in the L-P group (201.43 ± 22.87 min vs. 230.16 ± 51.44 min, P = 0.015). At a mean follow-up of 40.42 ± 18.43 months (range, 14-72 months), both reconstruction methods effectively ameliorated postoperative function. Patients who received L-P showed higher postoperative modified Mayo wrist scores (81.43 ± 5.49 vs. 71.13 ± 16.10, P = 0.003), Musculoskeletal Tumor Society scores (27.64 ± 1.34 vs. 25.06 ± 2.95, P = 0.004), and grip strength on the normal side (68.71% ± 8.00% vs. 57.81% ± 12.31%, P = 0.005) than the FA group. Better wrist extension (63.21° ± 8.99° vs. 45.32° ± 14.53°, P < 0.001) and flexion (45.36° ± 7.90° vs. 30.48° ± 12.07°, P < 0.001) were also observed in the L-P group. The complication rate was significantly higher in the FA group (29/31, 93.55%) than in the L-P group (1/14 7.14%, P < 0.001). The L-P group showed higher implant survival than the FA group, but the difference was not statistically significant., Conclusion: The cooperative application of LARS® and 3D-printed prostheses is an effective modality for reconstructing musculoskeletal defects after en bloc resection of distal radial GCTBs, which can improve functional outcomes, diminish complication rates, and promote wrist joint stability and motion., (© 2023 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
32. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
- Author
-
Duan DK, Zhang GC, Sun BJ, Ma TX, and Zhao M
- Subjects
- Humans, Denosumab therapeutic use, Bone Cements therapeutic use, Polymethyl Methacrylate, Knee Joint diagnostic imaging, Knee Joint surgery, Knee Joint pathology, Curettage adverse effects, Neoplasm Recurrence, Local pathology, Retrospective Studies, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Bone Neoplasms diagnostic imaging, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Bone Density Conservation Agents
- Abstract
Objective: Giant cell tumor of bone (GCTB) is a common primary bone tumor with latent malignant tendency. GCTB is prone to occur around the knee joint, and surgery is the major treatment method. There are relatively few reports on denosumab in the treatment of recurrent GCTB around the knee joint and postoperative function evaluation of patients. This research aimed to explore the appropriate surgical options for the treatment of recurrent GCTB around the knee joint., Patients and Methods: 19 patients with recurrent GCTB around the knee joint, who were admitted to Hospital for 3 months following denosumab treatment from January 2016 to December 2019, were included as the research subjects. The prognosis was compared between patients treated with curettage combined with polymethylmethacrylate (PMMA) and those with extensive-resection replacement of tumor prosthesis (RTP). A deep learning model of Inception-v3 combined with a Faster region-based convolutional neural network (Faster-RCNN) was constructed to classify and identify X-ray images of patients. The Musculoskeletal Tumor Society (MSTS) score, short form-36 (SF-36) score, recurrence, and the rate of complications were also analyzed during the follow-up period., Results: The results showed that the Inception-v3 model trained on the low-rank sparse loss function was obviously the best for X-ray image classification, and the classification and identification effect of the Faster-RCNN model was significantly better than that of the convolutional neural network (CNN), U-Net, and Fast region-based convolutional neural network (Fast-RCNN) models. During the follow-up period, the MSTS score in the PMMA group was significantly higher than that in the RTP group (p<0.05), while there was no significant difference in the SF-36 score, recurrence, and the rate of complications (p>0.05)., Conclusions: The deep learning model could improve the classification and identification of the lesion location in the X-ray images of GCTB patients. Denosumab was an effective adjuvant for recurrent GCTB, and widely extensive-resection RTP could reduce the risk of local recurrence after denosumab treatment for recurrent GCTB.
- Published
- 2023
- Full Text
- View/download PDF
33. Preoperative denosumab treatment in patients with giant cell bone tumors in limbs: A retrospective study using propensity score matching.
- Author
-
Huang Y, Xu M, Wang B, Zhao Z, Lin T, Huang G, Yin J, Xie X, Shen J, and Zou C
- Subjects
- Humans, Denosumab therapeutic use, Retrospective Studies, Propensity Score, Giant Cells pathology, Neoplasm Recurrence, Local pathology, Bone Density Conservation Agents therapeutic use, Bone Neoplasms pathology, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology
- Abstract
Background and Objectives: Denosumab is recommended for advanced giant cell tumor of bone (GCTB) that is unresectable or resectable with unacceptable morbidity. But the effect of preoperative denosumab treatment on the local control GCTB remains controversial., Methods: We conducted a study of 49 patients with GCTB in the limbs treated with denosumab before surgery and 125 patients without in our hospital from 2010 to 2017. Propensity-score matching (PSM) at a 1:1 ratio between the denosumab and control groups was performed to minimize possible selection bias, and compared the recurrence rate, limb function, and surgical degradation between the two groups., Results: The 3-year recurrence rates in the denosumab group and the control group were 20.4% and 22.9% after PSM, respectively (p = 0.702). In the denosumab group, 75.5% (n = 37/49) of patients experienced surgical downgrading. Limb joint preservation rates were 92.1% (35) for 38 patients treated with denosumab and 60.2% (71) for 118 control subjects. (p ≺ 0.001). Postoperative MSTS were higher in patients in the denosumab group than in the control group (24.1 vs. 22.6, p = 0.034)., Conclusions: Preoperative denosumab treatment did not result in an increased risk of local recurrence of GCTB. Patients with advanced GCTB may benefit from preoperative denosumab treatment for surgical downgrading and the preservation of the joint., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
34. An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report.
- Author
-
Nugraha HK, Wiratnaya IGE, and Astawa P
- Subjects
- Male, Humans, Femur surgery, Femur pathology, Curettage adverse effects, Neoplasm Recurrence, Local surgery, Neoplasm Recurrence, Local etiology, Bone Neoplasms diagnostic imaging, Bone Neoplasms surgery, Bone Neoplasms pathology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology
- Abstract
As a locally aggressive primary benign tumor, giant cell tumor of bone (GCTB) presents a challenge to surgeons, as it often recurs regardless of surgical resection. This report describes a case of GCTB of the distal femur in a man, aged 39 years, treated with intralesional curettage through an arthroscopic approach. A 360° view of the tumor cavity can be achieved with the help of an arthroscope, which can help complete intralesional curettage and minimize possible larger approach-related complications. The result is favorable in terms of functional outcome and recurrence after 1-year follow-up.
- Published
- 2023
- Full Text
- View/download PDF
35. Giant cell tumour of bone.
- Author
-
Aoude A, Nikomarov D, Perera JR, Ibe IK, Griffin AM, Tsoi KM, Ferguson PC, and Wunder JS
- Subjects
- Young Adult, Humans, Adult, Retrospective Studies, Neoplasm Recurrence, Local pathology, Bone Cements therapeutic use, Curettage methods, Fractures, Spontaneous etiology, Fractures, Spontaneous surgery, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms pathology
- Abstract
Giant cell tumour of bone (GCTB) is a locally aggressive lesion that is difficult to treat as salvaging the joint can be associated with a high rate of local recurrence (LR). We evaluated the risk factors for tumour relapse after treatment of a GCTB of the limbs. A total of 354 consecutive patients with a GCTB underwent joint salvage by curettage and reconstruction with bone graft and/or cement or en bloc resection. Patient, tumour, and treatment factors were analyzed for their impact on LR. Patients treated with denosumab were excluded. There were 53 LRs (15%) at a mean 30.5 months (5 to 116). LR was higher after curettage (18.4%) than after resection (4.6%; p = 0.008). Neither pathological fracture (p = 0.240), Campanacci grade (p = 0.734), soft-tissue extension (p = 0.297), or tumour size (p = 0.872) affected the risk of recurrence. Joint salvage was possible in 74% of patients overall (262/354), and 98% after curettage alone (262/267). Of 49 patients with LR after curettage, 44 (90%) underwent repeated curettage and joint salvage. For patients treated by curettage, only age less than 30 years (p = 0.042) and location in the distal radius (p = 0.043) predicted higher LR. The rate of LR did not differ whether cement or bone graft was used (p = 0.753), but may have been reduced by the use of hydrogen peroxide (p = 0.069). Complications occurred in 15.3% of cases (54/354) and did not differ by treatment. Most patients with a GCTB can undergo successful joint salvage by aggressive curettage, even in the presence of a soft-tissue mass, pathological fracture, or a large lesion, with an 18.4% risk of local recurrence. However, 90% of local relapses after curettage can be treated by repeat joint salvage. Maximizing joint salvage is important to optimize long-term function since most patients with a GCTB are young adults. Younger patients and those with distal radius tumours treated with joint-sparing procedures have a higher rate of local relapse and may require more aggressive treatment and closer follow-up., Competing Interests: None declared., (© 2023 The British Editorial Society of Bone & Joint Surgery.)
- Published
- 2023
- Full Text
- View/download PDF
36. Management of giant cell tumors of the distal radius: a systematic review and meta-analysis.
- Author
-
Koucheki R, Gazendam A, Perera J, Griffin A, Ferguson P, Wunder J, and Tsoi K
- Subjects
- Humans, Adult, Radius surgery, Curettage methods, Bone Transplantation, Retrospective Studies, Neoplasm Recurrence, Local pathology, Treatment Outcome, Giant Cell Tumor of Bone surgery, Bone Neoplasms surgery
- Abstract
Purpose: The treatment of giant cell tumors (GCT) of the distal radius remains challenging, with no consensus on the optimal surgical management. Surgical management remains the mainstay of treatment with options including intralesional curettage and en-bloc resection with reconstruction. The objective of this systematic review and meta-analysis was to evaluate and compare the outcomes of these two procedures., Methods: Using OVID-Medline and Embase databases, a systematic literature search was performed. Comparative studies, assessing intralesional curettage and en-bloc resection in patients with GCTs of the distal radius, were included. Data regarding rates of local recurrence, metastasis, overall complications, and functional outcomes, were collected and analyzed. The ROBINS-I tool was utilized for risk of bias appraisal within each study outcome., Results: Thirteen studies (n = 373 patients) reporting on 191 intralesional curettage procedures and 182 en-bloc resections were included in the analysis. The average age of participants was 31.9 (SD ± 2.4) years and average follow-up was 7.1 (SD ± 3.6) years. Patients that underwent intralesional curettage were more likely to develop local recurrence (Risk Ratio (RR) 3.3, 95% CI, [2.1, 5.4], p < 0.00001) when compared to patients that underwent en-bloc resection. In Campanacci grade 3 lesions, the risk for local recurrence was 5.9 (95% CI, [2.2, 16.3], p = 0.0006) times higher in patients that received intralesional curettage. Patients that underwent intralesional curettage showed an 84% reduction in the relative risk of developing overall complications compared to en-bloc resection (95% CI, [0.1, 0.4], p < 0.00001), and a larger decrease in Visual Analog Scale and lower Disabilities of the Arm, Shoulder, and Hand (DASH) scores (p < 0.00001). Risk ratio for developing a local recurrence, with PMMA versus bone graft following an intralesional procedure was not significant (RR 1.2, 95% CI, [0.6, 2.6], p = 0.62)., Conclusions: In the surgical management of GCT of the distal radius, intralesional curettage increased local recurrence compared to en-bloc resection with reconstruction, particularly in grade 3 tumors. However, it led to significantly fewer operative complications, lower pain scores, and improved functional outcomes compared to en-bloc resection. Both treatment options remain relevant in the contemporary management of GCTs of the distal radius. Surgical decision making should include both patient and tumor factors when determining the optimal treatment strategy for these patients. LEVEL 3 EVIDENCE: Meta-analysis of Level 3 studies., (© 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
37. The giant cell tumor during pregnancy: A review of literature.
- Author
-
Formica VM, Bruno V, Scotto Di Uccio A, Cocca E, Rossi B, and Zoccali C
- Subjects
- Child, Humans, Female, Adolescent, Male, Bone and Bones, Amputation, Surgical, Giant Cells pathology, Neoplasm Recurrence, Local surgery, Bone Neoplasms surgery, Giant Cell Tumor of Bone surgery
- Abstract
Background: Giant cell tumors (GTC) of bone are benign, locally aggressive tumors generally occurring in young people with a female predominance during reproductive age. Considering their worsening during pregnancy it has been suggested that pregnancy can accelerate GCT progression or favor recurrence but correlation between tumor growth and pregnancy has not yet been clarified. Aim of this study was to clarify clinical characteristics, timing and type of treatment through a literature review on GTCs occurring during pregnancy., Patients and Methods: An electronic search was performed in December 2020 in PubMed, Scopus, Embase, Medline, Cochrane Register using the keywords "giant cell tumor" AND "pregnancy" looking for papers reporting cases of giant cell tumors of the bone onset or recurred during pregnancy. The electronic search identified 212 papers; sixteen studies were selected, for a total of 32 cases., Results: The diagnosis was made during pregnancy in 24 cases and after the partum in 8 cases. 27 cases were new diagnoses while 5 cases were recurrences. Pulmonary metastases were reported in 3 patients. The treatment was performed during the pregnancy in 7 out of 32 cases; in the remaining 27 cases treatment was performed after delivery. The hormone receptor status was reported in 14 patients. Data regarding follow-up was reported for 26 out of 32 patients; three patients had local recurrences that were treated with wide resection and amputation in 2 and 1 case, respectively; at the last follow-up all patients were apparently without any evidence of disease except for three patients who had stable lung metastases., Discussion: In case of GCT during pregnancy, a multidisciplinary approach is necessary to offer the patients the best treatment in terms of mother and child's health. A correct diagnosis is necessary and not confusing tumor symptoms with ones of pregnancy is mandatory in order not to delay the diagnosis and let the tumor progress. Actually, even though pregnancy would seem to promote GCT growth and aggressiveness, the relationship is not clear. More studies are necessary to clarify this interesting aspect., Level of Evidence: IV, systematic review., (Copyright © 2022. Published by Elsevier Masson SAS.)
- Published
- 2023
- Full Text
- View/download PDF
38. Denosumab salvage therapy in an 11-year-old boy with locally recurrent unresectable giant cell tumor of the lumbar spine after surgery.
- Author
-
Luo Y, Xiu P, Chen H, Zeng J, Song Y, and Li T
- Subjects
- Male, Humans, Child, Denosumab therapeutic use, Treatment Outcome, Salvage Therapy, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local surgery, Neoplasm Recurrence, Local pathology, Lumbar Vertebrae surgery, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
Giant cell tumors (GCTs) of the bone are locally aggressive primary bone tumors with a benign character. Spinal involvement is rare which accounts for approximately 5% of all primary bone tumors and it is quite rare in the lumbar spine. An 11-year-old boy patient presented with pain of low back and bilateral low extremities. Lumbar CT and MRI revealed a lytic lesion of the L4 vertebra corpus. The patient earned remarkable and timely recovery with 2 surgical interventions and the use of denosumab. Surgical resection for GCTs is still preferable as the initial treatment, denosumab should be utilized after tumor resection whether based on the purpose of prevention or treatment of tumor recurrence., (Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
39. Giant Cell Tumor of the Thoracic Spine in a Young Female Patient in a México City Spine Center: A Case Report.
- Author
-
Chavira Torres OA, Cojuc-Konigsberg G, Becerril Vargas E, Haidenberg-David F, Dufoo Olvera M, Ladewig Bernáldez GI, Oropeza E, Bezzerri Colonna M, and Torres Santos SB
- Subjects
- Humans, Female, Young Adult, Adult, Mexico, Thoracic Vertebrae surgery, Giant Cells pathology, Spinal Neoplasms diagnostic imaging, Spinal Neoplasms surgery, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Thoracic Neoplasms pathology
- Abstract
BACKGROUND Giant cell tumors of the bone (GCTB) are rare, locally aggressive benign neoplasms that primarily occur in the metaphyses of long bones. In less than 2% of cases, GCTBs arise in the spine, predominantly below the sacrum. We report the clinical manifestations, diagnostic approach, and successful surgical treatment of a patient with a GCTB of the thoracic spine. CASE REPORT A 21-year-old female patient presented to the Emergency Department with back pain and upper motor neuron syndrome. A thorough clinical and imaging examination revealed a tumor and pathological fracture of the T7 vertebra. Histopathological analysis confirmed the diagnosis of a GCTB. The tumor was successfully excised surgically via a posterior thoracic approach, including bilateral decompressive laminectomy, lateral costotransversectomy, and posterior corpectomy, followed by transpedicular instrumentation of the T5-T6 and T8-T9 vertebrae, and anterior arthrodesis with an autologous graft. The patient also received adjuvant radiotherapy. One year later, the patient had no signs of recurrence or physical limitations. CONCLUSIONS GCTBs located in the thoracic spine are uncommon and pose a significant challenge for healthcare professionals due to their non-specific clinical manifestations and the need for a multidisciplinary approach to their management. This case highlights the diagnostic and therapeutic implications of a GCTB of the thoracic spine and describes a successful surgical strategy resulting in complete recovery. The presented case adds to the limited published literature on GCTBs in this unusual location and further elaborates on their presentation and management.
- Published
- 2023
- Full Text
- View/download PDF
40. Incidence and progression of osteoarthritis following curettage and cementation of giant cell tumor of bone around the knee: long-term follow-up.
- Author
-
Ebeid WA, Badr IT, Mesregah MK, and Hasan BZ
- Subjects
- Male, Female, Humans, Young Adult, Adult, Follow-Up Studies, Cementation, Incidence, Neoplasm Recurrence, Local complications, Curettage methods, Retrospective Studies, Giant Cell Tumor of Bone epidemiology, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone complications, Fractures, Spontaneous complications, Fractures, Spontaneous surgery, Bone Neoplasms epidemiology, Bone Neoplasms surgery, Osteoarthritis
- Abstract
Background: Giant cell tumor of bone (GCTB) is a benign locally aggressive tumor frequently treated with intralesional curettage and cementation. The aim of this study was to investigate the long-term incidence of arthritic changes following curettage and cementation of GCTB around the knee., Materials and Methods: This study was a retrospective review of patients with GCTB around the knee treated with curettage and cementation with a minimum follow-up of 10 years. The functional results were assessed using the Musculoskeletal Tumor Society (MSTS) score. The arthritic changes were classified using the Kellgren-Lawrence (KL) classification system of osteoarthritis., Results: This study included 119 patients, 54 males and 65 females, with a mean age of 29.4 ± 9.2 years. There were 35 (29.4%) patients with pathological fractures. There were 84 (70.6%) patients with de novo lesions and 35 (29.4%) with recurrent lesions. The mean follow-up period was 13.2 ± 3.16 years. The mean MSTS score was 28.5 ± 1.9. Overall, 25 (21%) patients developed variable degrees of arthritis of KL grade 1 (n = 7), KL grade 2 (n = 11), KL grade 3 (n = 4), and KL grade 4 (n = 3). Ten patients showed progression of arthritis during the follow-up period. Age at presentation, gender, presence of pathological fracture, whether the tumor was de novo or recurrent, and tumor location were not associated with arthritis incidence., Conclusions: Curettage and cementation can be used safely to treat GCTB around the knee. Arthritis of the knee is a possible complication, but mild grades are expected in most cases. There was no association between arthritis incidence and age, gender, pathological fractures, tumor location, or recurrent tumors., Level of Evidence: Level IV., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
41. CT-Guided RFA for Management of Surgical Relapses of Giant Cell Tumour of Bone.
- Author
-
Arrigoni F, Zoccali C, Evangelista L, Giuliani L, Daffinà J, Zugaro L, and Masciocchi C
- Subjects
- Humans, Treatment Outcome, Retrospective Studies, Tomography, X-Ray Computed methods, Recurrence, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Catheter Ablation methods
- Abstract
Objectives: This retrospective study describes a pilot experience in CT-guided RadioFrequency Ablation (RFA) treatment of 5 Giant Cell Tumour of the bone (GCT) recurrences after surgery., Methods: After biopsy to confirm the diagnosis of GCT recurrences, all patients were treated with RFA in a single session. A close follow-up was scheduled with contrast-enhanced MRI starting 1 months after treatment., Results: Five lesions were treated in 5 patients. The length of the observation period was between 4 and 100 months. One lesion relapsed 4 months after the RFA treatment, and the patient underwent a second surgical treatment which included the en-block resection and prosthetic implant. No complications were recorded., Conclusions: The management of GCT relapses with RFA could be an interesting and innovative field. However, the results of this limited series need to be confirmed by further investigations of larger patient cohorts., (© 2023. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).)
- Published
- 2023
- Full Text
- View/download PDF
42. A rare case of malignancy of giant cell tumor of distal end radius: a clinical image.
- Author
-
Jobanputtra Y and Patil D
- Subjects
- Humans, Radius diagnostic imaging, Treatment Outcome, Bone Transplantation, Giant Cell Tumors, Neoplasms, Bone Neoplasms pathology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery
- Published
- 2023
- Full Text
- View/download PDF
43. Giant cell tumor of bone with H3F3B mutation: A case report.
- Author
-
Wu R, Wu X, Weng X, Xiu Y, Xu G, Liu X, and Liu X
- Subjects
- Humans, Male, Middle Aged, Diagnosis, Differential, Histones metabolism, Mutation, Bone Neoplasms pathology, Giant Cell Tumor of Bone diagnosis, Giant Cell Tumor of Bone genetics, Giant Cell Tumor of Bone surgery
- Abstract
Rationale: Giant cell tumor of bone is a locally aggressive and rarely metastasizing neoplasm that typically affects the ends of long bones or the axial skeleton of young to middle-aged adults. As many as 69% to 100% of giant cell tumors harbor H3F3A gene mutations, while H3F3B gene mutations have rarely been reported., Patient Concerns: A 53-year-old male patient who underwent right distal femoral tumor resection., Diagnoses: Preoperative CT plain scan indicated giant cell tumor of bone with pathological fracture. Laboratory findings were as follows: serum calcium was 2.23 mmol/L (reference range: 2.1-2.55 mmol/L) and serum phosphorus was 1.35 mmol/L (reference range: 0.81-1.45 mmol/L)., Interventions: The histological morphology showed the typical features of a conventional GCT. The immunoprecipitation analysis results were as follows: H3.3G34W(-), H3.3G34R(-), H3.3G34V(-), and H3K36M(-). Sanger sequencing showed that the H3F3A and H3F3B gene mutations were wild type. The high-throughput gene sequencing results revealed the H3F3B gene mutations H3.3p.Gly35Trp and H3.3p.Val36Leu., Outcomes: The patient was stable with no recurrence in 12 months follow-up., Lessons: Giant cell tumor of bone with H3F3B gene mutations is extremely rare. In the pathological diagnosis of bone tumors, we need to analyze clinical presentation, imaging features, histology, immunophenotype, and cytogenetic/molecular alterations, in order to get a correct diagnosis., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
44. Association between preoperative denosumab and the risk of local recurrence in patients with giant cell tumor of bone: A meta-analysis and systematic review.
- Author
-
Sun Z, Wu Z, Zhang L, Jia Q, Zhou Z, and Xiao J
- Subjects
- Humans, Denosumab adverse effects, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local pathology, Retrospective Studies, Bone Density Conservation Agents, Bone Neoplasms drug therapy, Bone Neoplasms pathology, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology
- Abstract
Objectives: This meta-analysis aimed at determining the association between preoperative denosumab and the risk of local recurrence in patients with giant cell tumors of the bone., Methods and Materials: Web of Science, EMBASE, Cochrane Library, and PubMed were comprehensively searched on April 20
th , 2022. Data from the included articles were analyzed using meta-analysis. The bias of all included studies was evaluated according to ROBINS-I. Also, subgroup and sensitivity analyses were performed., Results: Eight studies with 1270 cases (195 in the denosumab group and 1075 in the control group) were eventually included. Patients receiving denosumab before curettage had a higher risk of local recurrence than those who underwent curettage alone (odds ratio: 2.29, 95% confidence intervals: 1.44-3.64, P = 0.0005). The denosumab group showed a significantly higher risk of local recurrence in most subgroup analyses, except for those with preoperative denosumab duration ≤six months/doses (P = 0.66) and sample size ranging from 100 to 180 (P = 0.69)., Conclusion: Denosumab before curettage may increase the risk of local recurrence in patients with giant cell tumor of the bone. Preoperative denosumab should be used with caution after weighing an increased risk of local recurrence against the clinical benefits and a duration time of less than six months before surgery is recommended., Competing Interests: None- Published
- 2023
- Full Text
- View/download PDF
45. Diffuse Pulmonary Metastases at Presentation of Giant Cell Tumor of Bone: A Case Report and Synthesis of Literature.
- Author
-
Leland CR, Pratilas CA, Gross JM, and Levin AS
- Subjects
- Male, Young Adult, Humans, Adult, Bone Neoplasms surgery, Giant Cell Tumor of Bone surgery, Lung Neoplasms secondary
- Abstract
Case: We present a 23-year-old man with acute-on-chronic shoulder pain with an aggressive-appearing, destructive lesion of the left proximal humerus and diffuse lung metastases. Biopsy revealed conventional giant cell tumor of bone (GCTB) without sarcomatous differentiation, treated with resection and proximal humerus reconstruction. Without systemic treatment, his pulmonary metastases demonstrated modest spontaneous regression, with no impairment of pulmonary function., Conclusions: Although GCTB is known to metastasize to lungs, these deposits most commonly follow local recurrence. We describe a young adult with diffuse pulmonary nodules at initial presentation, although still following an indolent clinical course without the need for additional systemic therapy., Competing Interests: Each author certifies that he or she, nor any members of their immediate families, has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSCC/B994)., (Copyright © 2023 by The Journal of Bone and Joint Surgery, Incorporated.)
- Published
- 2023
- Full Text
- View/download PDF
46. Giant Cell Tumor of the Distal Radius: A Review.
- Author
-
Hess MC, Kafchinski L, and Ransom E
- Subjects
- Humans, Radius surgery, Treatment Outcome, Wrist Joint surgery, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology, Bone Neoplasms surgery, Bone Neoplasms pathology
- Abstract
Giant cell tumor of the distal radius presents a significant challenge in management due to high risk of recurrence and potential loss of function. Shared decision-making guides management, particularly for more advanced lesions. Intralesional curettage can optimize wrist function but at the cost of a higher recurrence risk. Wide resection decreases local recurrence but has higher complication rates regardless of reconstruction method. No functional difference exists between motion-preserving procedures and arthrodesis; therefore, patients should be clearly informed of the risks and benefits of each treatment option., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
47. Resection and reconstruction with and without neoadjuvant denosumab in campanacci grade III giant cell tumors of proximal humerus: a retrospective comparative study.
- Author
-
Sahito B, Ali SME, Farooqui SF, Abro A, Ahmed J, and Younis
- Subjects
- Humans, Retrospective Studies, Shoulder, Neoadjuvant Therapy, Treatment Outcome, Humerus surgery, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Bone Neoplasms pathology, Giant Cell Tumors pathology, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Giant Cell Tumor of Bone pathology
- Abstract
Background: Giant cell tumors (GCT) of the proximal humerus are rarely reported case that requires complex surgeries due to involvement of the shoulder joint. Therefore, we report the first retrospective comparative study where the postoperative functional outcomes, recurrence rate and complications in patients who underwent arthrodesis of shoulder after resection of grade III GCT with and without neoadjuvant denosumab are compared., Methods: A retrospective review of eight cases of grade III GCT of proximal humerus receiving resection and fibular strut graft and arthrodesis between January 2014 and December 2019 is performed. They were stratified into two groups: one group of four patients received once-weekly denosumab 120 mg for 4-weeks before resection and reconstruction, while the other group of four patients did not receive denosumab before surgery. Primary outcomes included the functional outcomes assessed by revised Musculoskeletal tumor society (MSTS) score and shoulder pain and disability index (SPDI) at 6-weeks and 12-months postoperatively while secondary outcomes included complications and recurrences., Results: There was no significant difference in terms of SPDI at 6 weeks and 12 months, MSTS at 12 months, complications, recurrence among denosumab and non-denosumab groups. At 6-weeks follow-up, a significantly better pain score in SPDI and MSTS was acquired in the denosumab group., Conclusions: Resection and reconstruction with or without neoadjuvant denosumab for Grade III GCT of proximal humerus had similar functional outcomes and with no major differences in recurrence and complications. Hence, postoperative pain relief while long-term benefits were not discovered with the use of neoadjuvant denosumab., (© 2021. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
48. Comparing clinical outcomes between extended curettage and wide resection in Enneking stage 3 giant cell tumor of bone.
- Author
-
Tuntarattanapong P, Piakong P, Chobpenthai T, Sukanthanak B, and Kiatisevi P
- Subjects
- Humans, Retrospective Studies, Curettage methods, Neoplasm Recurrence, Local pathology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone surgery, Bone Neoplasms pathology, Cartilage, Articular
- Abstract
Purpose: Our objectives were (1) to compare the recurrence, metastases, and complication rates of patients with Enneking stage 3 GCTB who underwent extended curettage vs wide resection and (2) examine the factors which might influence surgical options for each patient., Methods: We retrospectively reviewed the records of patients with Enneking stage 3 GCTB from January 2006-December 2015. Extended curettage was performed in patients in whom there was a moderate expansile lesion, minimal/no articular cartilage damage, and less than 50% of cortical deformation compared to its circumference from a CT scan/MRI. The percentages of cortical deformation were collected. Surgical complications, recurrence, and metastatic rates were analyzed., Results: There were 28 extended curettage and 41 wide resections. The mean percentages of cortical deformation compared to circumference were 52.6% (range, 23.9-81.9%) and 91.6% (range, 52.1-100%)(P < 0.01) for the curettage and wide resection groups, respectively. There were three recurrences, 2/28 (7.1%) from the curettage group and 1/41 (2.4%) from the resection group (P = 0.56). There were no cases of pulmonary metastasis. There were two complications in the curettage group and five complications in the resection group., Conclusion: Both extended curettage and wide resection are useful methods to treat Enneking stage 3 GCTB. Extended curettage with proper technique is a viable option showing no difference in local recurrence rate and potentially fewer complications. Preference to do extended curettage in patients in whom when the articular cartilage has minimal or no destruction, a moderate expansile lesion and the cortical deformation is less than 50% of the circumference., (© 2021. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
49. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
- Author
-
Tsukamoto S, Hindiskere S, Honoki K, Mavrogenis AF, Tanaka Y, Chinder PS, Donati DM, and Errani C
- Subjects
- Humans, Denosumab therapeutic use, Retrospective Studies, Curettage, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local prevention & control, Bone Density Conservation Agents adverse effects, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Bone Neoplasms complications
- Abstract
Purpose: Denosumab enables joint-sparing surgery (curettage) and surgical downstaging in patients with giant cell tumour of bone (GCTB), where joint preservation is not possible. However, denosumab treatment causes osteosclerosis of the lesion, making it difficult to curet the lesion, leaving the tumour behind, and increasing the local recurrence rate. We performed a three-centre retrospective study to investigate the postoperative local re-recurrence rate, joint preservation status, and functional outcomes of locally recurrent lesions after preoperative denosumab treatment and curettage in patients with difficult joint preservation., Methods: We included 38 of 142 patients with primary GCTB of the extremities who underwent preoperative denosumab and curettage between 2009 and 2021 with local recurrence. Preoperative denosumab was indicated in patients with minimal residual periarticular and subchondral bones, large extraosseous lesions (Campanacci stage 3), and pathological fractures that made joint preservation difficult., Results: Local re-recurrence occurred in 6 (15.8%) of the 38 patients. In 29 patients who underwent re-curettage, local re-recurrence occurred in six patients (20.7%); however, in nine patients who underwent en bloc resection, no local re-recurrence was observed. The joint preservation rate was 63.2% (24 of 38 patients), with a median Musculoskeletal Tumor Society score of 28 (interquartile range: 26.8-29.0). The median follow-up period after surgery for local recurrence was 63.5 months (interquartile range: 42.5-82.4)., Conclusion: Since the local re-recurrence rate after re-curettage for local recurrence was low, and the joint preservation rate and affected limb function were good, preoperative denosumab administration may be considered in patients who require downstaging to maintain good limb function (joint preservation)., (© 2022. The Author(s) under exclusive licence to SICOT aisbl.)
- Published
- 2023
- Full Text
- View/download PDF
50. Mid-term results of giant cell tumours with pathologic fractures around the knee: a multicentre retrospective study.
- Author
-
Zhao L, Chen J, Hu Y, Ye Z, and Tao K
- Subjects
- Humans, Adolescent, Young Adult, Adult, Middle Aged, Aged, Retrospective Studies, Neoplasm Recurrence, Local surgery, Treatment Outcome, Fractures, Spontaneous etiology, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone epidemiology, Giant Cell Tumor of Bone surgery, Bone Neoplasms complications, Bone Neoplasms diagnostic imaging, Bone Neoplasms epidemiology
- Abstract
Objective: The aims of this work are to present a classification of "complex fracture" and "simple fracture", to compare their features, treatments and prognosis in patients with giant cell tumour with pathologic fractures around the knee, and to determine the best surgical method for patients who have giant cell tumour around the knee with different degrees of fracture., Methods: Data from 130 patients with pathologic fractures from giant cell tumour around the knee who underwent surgical treatment from March 2000 to November 2015 at 6 institutes around China were collected and analysed. A multicentric study design was used to explore the epidemiological features and to compare differences in the surgical procedures and prognosis of the two fracture groups. The mean age at diagnosis was 37.1 years old (range, 13-77 years). The median follow-up was 126.5 months, ranging from 68 to 370 months., Results: The general clinical and imaging features of the groups of patients with simple and complex fractures, namely, sex, age, the lesion site, living or working environment, eccentric growth patterns, Campanacci grading system, and duration of symptoms before treatment, showed varying degrees of differences, but with no statistical significance (p > 0.05). The incidence rate of surrounding soft tissue mass was 35.2% (32/91) in the group with simple fractures, whereas it was 87.2% (34/39) in the group with complex fractures, which showed a significant difference (p < 0.05). Wide resection and reconstruction with joint replacement were performed more often in patients with complex fractures (61.5%, 24/39). Intralesional procedures were performed more often in patients with simple fractures (56.0%, 51/91). The difference showed significant differences (p < 0.05). The local recurrence rate was 17.6% (16/91) in the group with simple fractures, whereas it was 10.3% (4/39) in the complex fracture group, showing a significant difference (p < 0.05). A total of 2.3% of patients (n = 3,3/130) developed a skip lesion. The complication rates were 4.6% (4/87) and 14.7% (5/34), respectively, in the two groups with simple or complex fractures, showing a significant difference (p < 0.05). The mean MSTS and TESS scores with simple fractures were 26.6 (range, 13-30) and 84.1 (range, 29-100), respectively, whereas the mean scores in the group with complex fractures were 25.5 (range, 18-30) and 78.3 (range, 30-100), respectively, also showing a significant difference (p < 0.05)., Conclusion: Our classification of "simple fracture" and "complex fracture" could guide decisions regarding the best surgical method for lesions in patients who have giant cell tumour around the knee with different degrees of fracture., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.